English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In a recent article, Lee et al. ([4][1]) reported the occurrence of an increase in MICs for polymyxin B during therapy in 3 of 16 patients treated with this drug for carbapenem-resistant Klebsiella pneumoniae infections. This report is very important, since polymyxins, polymyxin B and colistin, are

journal of clinical microbiology

Stable Polymyxin B Susceptibility to <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter</i> spp. despite Persistent Recovery of These Organisms from Respiratory Secretions of Patients with Ventilator-Associated Pneumonia Treated with This Drug

Stable Polymyxin B Susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite Persistent Recovery of These Organisms from Respiratory Secretions of Patients with Ventilator-Associated Pneumonia Treated with This Drug